Plain-English translation of NCT06805825 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called , which is a type of antibody-drug combination designed to target and attack cancer cells that have a specific protein called c-Kit on their surface. The study has two phases: first, doctors will test different doses to find the safest level, and then they will study how well the medication works at that dose in people with specific types of cancer.
Many people with advanced cancers like gastrointestinal stromal tumors, small-cell lung cancer, and other rare tumors have limited treatment options, especially when standard therapies stop working or cause too many side effects. This medication is being tested as a new option to help patients whose cancers express the c-Kit protein.
You likely qualify if…
You likely don't qualify if…
You will receive the medication as an IV infusion once every three weeks. The trial has two parts: in the first part, doctors gradually increase doses in small groups of patients to find the safest dose level. In the second part, larger groups of patients with specific cancer types receive the medication at the dose determined to be safe. Throughout the study, you will have regular blood tests, heart monitoring, and imaging scans to check how you are tolerating the treatment and whether your cancer is responding.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
United States